This paper reports the development and characterization of monoclonal antibodies (mAbs) that potently neutralize SARS-CoV-2 variants. Using high-throughput single-cell sequencing of B cells from immunized animals, two potent neutralizing mAb clones were identified, and a bispecific antibody was generated. Cryo-EM structures were solved, revealing distinct epitopes and binding patterns. The mAbs showed potent efficacy in vivo, and a humanized antibody maintained strong potency against the original virus and the Delta variant. These findings expand the therapeutic options against SARS-CoV-2 and its variants.
Publisher
NATURE COMMUNICATIONS
Published On
Mar 28, 2022
Authors
Lei Peng, Yingxia Hu, Madeleine C. Mankowski, Ping Ren, Rita E. Chen, Jin Wei, Min Zhao, Tongqing Li, Therese Tripler, Lupeng Ye, Ryan D. Chow, Zhenhao Fang, Chunxiang Wu, Matthew B. Dong, Matthew Cook, Guilin Wang, Paul Clark, Bryce Nelson, Daryl Klein, Richard Sutton, Michael S. Diamond, Craig B. Wilen, Yong Xiong, Sidi Chen
Tags
monoclonal antibodies
SARS-CoV-2
neutralization
high-throughput sequencing
therapeutic options
variants
in vivo efficacy
Related Publications
Explore these studies to deepen your understanding of the subject.
